NO751118L - - Google Patents
Info
- Publication number
- NO751118L NO751118L NO751118A NO751118A NO751118L NO 751118 L NO751118 L NO 751118L NO 751118 A NO751118 A NO 751118A NO 751118 A NO751118 A NO 751118A NO 751118 L NO751118 L NO 751118L
- Authority
- NO
- Norway
- Prior art keywords
- interferon
- solution
- agent
- urea
- approx
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 claims description 95
- 108010050904 Interferons Proteins 0.000 claims description 95
- 229940079322 interferon Drugs 0.000 claims description 95
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 25
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 23
- 239000004202 carbamide Substances 0.000 claims description 23
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 9
- 239000003945 anionic surfactant Substances 0.000 claims description 7
- 125000000129 anionic group Chemical group 0.000 claims description 6
- 239000003093 cationic surfactant Substances 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 claims description 6
- 239000007858 starting material Substances 0.000 claims description 5
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- 239000000243 solution Substances 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 13
- 238000009835 boiling Methods 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000006641 stabilisation Effects 0.000 description 6
- 238000011105 stabilization Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- XZTJQQLJJCXOLP-UHFFFAOYSA-M sodium;decyl sulfate Chemical compound [Na+].CCCCCCCCCCOS([O-])(=O)=O XZTJQQLJJCXOLP-UHFFFAOYSA-M 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL7404589A NL7404589A (nl) | 1974-04-03 | 1974-04-03 | Werkwijze voor het stabiliseren van interferon. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO751118L true NO751118L (da) | 1975-10-06 |
Family
ID=19821109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO751118A NO751118L (da) | 1974-04-03 | 1975-04-02 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US3981991A (da) |
| JP (1) | JPS5132725A (da) |
| AU (1) | AU7951275A (da) |
| BE (1) | BE826889A (da) |
| DE (1) | DE2514537A1 (da) |
| DK (1) | DK139775A (da) |
| FI (1) | FI750951A (da) |
| FR (1) | FR2266740B3 (da) |
| NL (1) | NL7404589A (da) |
| NO (1) | NO751118L (da) |
| SE (1) | SE7503769L (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4100150A (en) * | 1975-11-04 | 1978-07-11 | G. D. Searle & Co. | Stabilization of interferon against mechanical stress using thioctic acid |
| FR2351665A1 (fr) * | 1976-05-21 | 1977-12-16 | Elf Aquitaine | Procede de purification de preparations possedant notamment une activite interferon, preparations purifiees ainsi obtenues et leur application en tant que medicament |
| US4503035B1 (en) * | 1978-11-24 | 1996-03-19 | Hoffmann La Roche | Protein purification process and product |
| IN150740B (da) * | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
| US6410697B1 (en) | 1979-04-20 | 2002-06-25 | Schering Corporation | Process for purifying human leukocyte interferon |
| US4289689A (en) * | 1980-03-14 | 1981-09-15 | Hoffmann-La Roche Inc. | Preparation of homogeneous human fibroblast interferon |
| US4252791A (en) * | 1979-10-19 | 1981-02-24 | The Medical College Of Wisconsin, Inc. | Interferon stabilization |
| IL62552A0 (en) | 1980-04-03 | 1981-06-29 | Biogen Nv | Dna sequences,recombinant dna molecules and processes for producing human fibroblast interferon-like polypeptides |
| DE3278234D1 (en) * | 1981-10-13 | 1988-04-21 | Exovir Inc | Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis |
| US5582824A (en) * | 1981-10-19 | 1996-12-10 | Genentech, Inc. | Recombinant DES-CYS-TYR-CYS human immune interferon |
| EP0080879B1 (en) * | 1981-11-28 | 1986-10-01 | Sunstar Kabushiki Kaisha | Pharmaceutical composition containing interferon in stable state |
| JPS58167520A (ja) * | 1982-03-27 | 1983-10-03 | Sunstar Inc | インタ−フエロン安定配合製剤 |
| US5702699A (en) * | 1982-09-23 | 1997-12-30 | Cetus Corporation | Process for the recovery of lipophilic proteins |
| US4681930A (en) * | 1983-09-20 | 1987-07-21 | Hoffmann-La Roche Inc. | Immune interferon and a method for its extraction and purification |
| ZA846554B (en) * | 1983-09-20 | 1985-04-24 | Hoffmann La Roche | Immune interferon and method for its purification |
| US4476049A (en) * | 1983-09-20 | 1984-10-09 | Hoffmann-La Roche Inc. | Method for the extraction of immune interferon |
| JPS6079000A (ja) * | 1983-10-04 | 1985-05-04 | Takeda Chem Ind Ltd | ヒトγ型インタ−フエロン単量体の製造法 |
| MX9203641A (es) * | 1983-12-16 | 1992-07-01 | Genentech Inc | Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion. |
| US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
| IL74094A0 (en) * | 1984-01-23 | 1985-04-30 | Takeda Chemical Industries Ltd | Highly solubilised protein and production thereof |
| JPS62500237A (ja) * | 1984-09-21 | 1987-01-29 | フセソユズニ ナウチノ−イススレドバテルスキ インステイテユト オソボ チステイフ ビオプレパラトフ | ヒト白血球インタ−フェロンの精製方法 |
| JPS61277633A (ja) * | 1985-05-31 | 1986-12-08 | Toray Ind Inc | インタ−フエロン組成物 |
| JP2577742B2 (ja) * | 1986-07-18 | 1997-02-05 | 中外製薬株式会社 | 安定な顆粒球コロニ−刺激因子含有製剤 |
| US4950470A (en) * | 1986-10-06 | 1990-08-21 | Board Of Regents, The University Of Texas System | Methods and compositions employing interferon-gamma |
| US5165921A (en) * | 1989-01-23 | 1992-11-24 | National Geno Sciences, Inc. | Method for treating condyloma acuminatum with interferon |
| US5236707A (en) * | 1991-11-08 | 1993-08-17 | Dallas Biotherapeutics, Inc. | Stabilization of human interferon |
| US6399296B1 (en) * | 1994-07-20 | 2002-06-04 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
| GB0002660D0 (en) * | 2000-02-04 | 2000-03-29 | Biomade B V | Method of stabilizing a hydrophobin-containing solution and a method of coatinga surface with a hydrophobin |
| UY27373A1 (es) * | 2001-07-09 | 2003-02-28 | Schering Ag | Formulaciones de interferón beta-humano |
-
1974
- 1974-04-03 NL NL7404589A patent/NL7404589A/xx not_active Application Discontinuation
-
1975
- 1975-03-20 BE BE1006541A patent/BE826889A/xx unknown
- 1975-03-26 AU AU79512/75A patent/AU7951275A/en not_active Expired
- 1975-03-27 FI FI750951A patent/FI750951A/fi not_active Application Discontinuation
- 1975-04-02 FR FR7510302A patent/FR2266740B3/fr not_active Expired
- 1975-04-02 NO NO751118A patent/NO751118L/no unknown
- 1975-04-02 DK DK139775A patent/DK139775A/da unknown
- 1975-04-02 SE SE7503769A patent/SE7503769L/xx unknown
- 1975-04-03 JP JP50040754A patent/JPS5132725A/ja active Pending
- 1975-04-03 DE DE19752514537 patent/DE2514537A1/de not_active Withdrawn
- 1975-04-03 US US05/564,723 patent/US3981991A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5132725A (da) | 1976-03-19 |
| SE7503769L (sv) | 1975-10-06 |
| BE826889A (nl) | 1975-09-22 |
| FR2266740B3 (da) | 1977-12-16 |
| AU7951275A (en) | 1976-09-30 |
| FR2266740A1 (da) | 1975-10-31 |
| US3981991A (en) | 1976-09-21 |
| DE2514537A1 (de) | 1975-10-09 |
| FI750951A (da) | 1975-10-04 |
| NL7404589A (nl) | 1975-10-07 |
| DK139775A (da) | 1975-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO751118L (da) | ||
| NO751117L (da) | ||
| Müller et al. | The two segments of the infectious bursal disease virus genome are circularized by a 90,000-Da protein | |
| Marmur et al. | Denaturation of deoxyribonucleic acid by formamide | |
| EP0722492B1 (en) | Stabilisation of proteins in solution | |
| JP2002531119A (ja) | ウイルスを保存するための方法および組成物 | |
| SE445148B (sv) | Forfarande for framstellning av en biologisk komposition for anvendning som en referenskomposition for blodserum vid diagnostisk analys | |
| Tateishi et al. | C-terminal truncated Escherichia coli RecA protein RecA5327 has enhanced binding affinities to single-and double-stranded DNAs | |
| Hartshorne et al. | The effect of temperature on actomyosin | |
| US3933996A (en) | Composition comprising radioactive labeled-fibrinogen and albumin | |
| Centrella et al. | Regulation of protein synthesis in vesicular stomatitis virus-infected mouse L-929 cells by decreased protein synthesis initiation factor 2 activity | |
| KR970701199A (ko) | 성장 정지 호메오박스 유전자(Growth Arrest Homeobox Gene) | |
| Chung et al. | Purification and properties of tuna myosin | |
| JP4010573B2 (ja) | 低温殺菌中の血漿を安定化するための組成物および治療学的用途のための低温殺菌血漿溶液 | |
| TAGUCHI et al. | Protein‐protein interaction of fish myosin fragments | |
| Alais et al. | Isolation, purification, and analysis of two κ-casein-like fractions from sheep casein | |
| Fantl | A comparative study of blood coagulation in vertebrates | |
| JPS6237010B2 (da) | ||
| Christensen | Protamine purification of streptokinase and effect of pH and temperature on reversible inactivation | |
| Meyer et al. | Structural studies of the RNA component of the poliovirus replication complex II. Characterization by electron microscopy and autoradiography | |
| Wong | Histone H3 thiol reactivity as a probe of nucleosome structure | |
| Cesario et al. | Relationship between the physicochemical nature of human interferon, the cell induced, and the inducing agent | |
| Stewart II et al. | Protective effects of anionic detergents on interferons: reversible denaturation | |
| Gould et al. | An examination of models for chromatin transcription | |
| FI57534C (fi) | Foerfarande foer foerbaettrandet av stabiliteten vid rumstemperatur hos ett oralt poliovirusvaccin av typen 1, 2 eller 3 |